Global tuberculosis report

Launched 29 October 2024

Main findings and messages



Acknowledgements

193 countries and areas that reported data

>500 people who contributed to reporting and review of data

Core Report Team, WHO HQ

Taghreed Adam, Nim Arinaminapathy, Annabel Baddeley, Mathieu Bastard, Saskia den Boon, Dennis Falzon, Katherine Floyd, Nebiat Gebreselassie, Irwin Law, Hazim Timimi, Takuya Yamanaka

Other WHO staff: HQ, regional and country offices

Jean Louis Abena Foe, Pedro Avedillo, Kenza Bennani, Vineet Bhatia, Delia Boccia, Martin van den Boom, Annemieke Brands, Maria Regina Christian, Francesca Conradie, Monica Dias, Michel Gasana, Inés Garica Baena, Medea Gegia, Licé Gonzalez Angulo, Christian Gunneberg, Akudo Ikpeazu, Jean Iragena, Tauhid Islam, Ernesto Jaramillo, Avinash Kanchar, Tereza Kasaeva, Alexei Korobitsyn, Giorgi Kuchukhidze, Marek Lalli, Franciso León, Farai Mavhunga, Cecily Miller, Francis Mhimbira, Fuad Mirzayev, Ernesto Montoro, Fukushi Morishita, Carl-Michael Nathanson, Linh Nguyen, Cicilia Gita Parwati, Kyung Oh, Kalpeshsinh Rahevar, Md Kamar Rezwan, Samuel Schumacher, Anna Stukulova, Lana Syed, Sabine Verkuijl, Kerri Viney, Elena Vovc, Yi Wang, Manami Yanagawa, Askar Yedilbayev, Matteo Zignol; plus all focal points for TB in WHO country offices

Other key contributors to report content

Pete Dodd (Sheffield University, UK)

Funding

USAID; governments of France and Republic of Korea



Background/context



Report purpose

The report provides a comprehensive and up-to-date assessment of the TB epidemic and of progress in the response at global, regional and country levels, in the context of global commitments, strategies and targets

WHO End TB Strategy, 2016-2035
UN Sustainable Development Goals, 2016-2030
2023 UN high-level meeting on TB



WHO End TB Strategy

2016-2035

INDICATORS	MILESTONES		TARGETS	
	2020	2025	2030	2035
1. Reduction in number of TB deaths compared with 2015 (%)	35%	75%	90%	95%
2. Reduction in TB incidence rate compared with 2015 (%)	20%	50%	80%	90%
3. Percentage of TB patients and their households facing catastrophic costs due to TB	Zero	Zero	Zero	Zero



UN Sustainable Development Goals

2016-2030

SDG Target 3.3 includes ending the TB epidemic

TB incidence rate is indicator for assessment of progress



2023 UN high-level meeting on TB Global targets

Indicator	Global Target
TB treatment coverage	90% by 2027
Coverage of TB preventive treatment for priority groups (household contacts of people with TB; people living with HIV)	90% by 2027
Coverage of rapid diagnostic testing for TB	100% by 2027
Coverage of health and social benefits package for people with TB	100% by 2027
Availability of new TB vaccines that are safe and effective	Rollout initiated, preferably within 5 years
Annual funding for universal access to quality prevention, diagnosis, treatment and care for TB	US\$ 22 billion by 2027, US\$ 35 billion by 2030
Annual funding for TB research	US\$ 5 billion by 2027



Main sources of data



Main source of data for report

Annual rounds of global TB data collection from 215 countries and areas

WHO Region	Countries and areas that reported data in 2024	WHO Member States that reported data in 2024
Africa	47/47	47/47
Americas	40/45	34/35
Eastern Mediterranean	21/22	20/21
Europe	40/54	39/53
South-East Asia	11/11	11/11
Western Pacific	34/36	27/27
All regions	193/215	178/194

Plus: SDG, OECD & World Bank databases

Datasets and estimates from UNAIDS

WHO mortality database and Global Health Observatory

Data from national TB prevalence surveys, drug resistance surveys, inventory studies



Main topics



Six main topics covered in the report

- 1. TB disease burden
- 2. TB diagnosis & treatment
- 3. TB prevention & screening
- 4. TB financing
- 5. Universal health coverage & TB determinants
- 6. TB research



Featured topics (on webpages)

- 1. TB & pregnancy
- 2. The second national TB inventory study in Indonesia
- 3. Asymptomatic TB
- 4. Multisectoral accountability in the TB response
- 5. Community and civil society engagement in the TB response



Overarching findings and headline numbers



Overarching findings

Although ending the global TB epidemic remains a distant goal, there are several positive trends

- Global rise in number of people falling ill with TB has slowed and started to stabilize
- Global number of people dying from TB each year continues to fall
- WHO African and European regions have made good progress towards the 2025 milestones for reductions in TB incidence and mortality
- Globally reported number of people newly diagnosed with TB reached new high in 2023
- Treatment success rate for people with drug-susceptible TB has been sustained at a high level and continues to improve for people with drug-resistant TB
- Coverage of TB preventive treatment has been sustained for people living with HIV and continues to improve for household contacts of people diagnosed with TB



Headline global numbers 2023 unless stated

- Incident TB cases: 10.8 million (95% UI: 10.1-11.7 million)
 - rate, 134 per 100,000 population
- TB deaths: 1.25 million (95% UI: 1.13-1.37 million)
 - 1.09 million among HIV-negative people
 - 161k among people with HIV*
- Number of people newly diagnosed with TB and reported: 8.2 million
- Treatment success rate, drug-susceptible TB (enrolled in 2022): 88%
- Incident cases of MDR/RR-TB: 400k (95% UI: 360-440k)
- Number of people enrolled on treatment for MDR/RR-TB: 176k
- Treatment success rate, MDR/RR-TB (enrolled in 2021): 68%
- Number of people provided with TB preventive treatment: 4.7 million




Estimates of TB disease burden



Global rise in TB incidence slowing, starting to stabilize

Best estimate of 10.8 million in 2023, small rise from 10.7 million in 2022




Most of the increase between 2022 and 2023 due to population growth



Global TB incidence rate almost stabilized

0.2% increase between 2022 and 2023




Best estimate of 134 per 100 000 population in 2023, virtually the same as in 2022

8.3% below the 2015 level of 147




8 countries, 67% of global cases in 2023

87% in 30 high TB burden countries




Most TB cases among adults, more men than women

55% men, 33% women, 12% children and young adolescents (<15 years)






Further fall in global number of deaths from TB, continuing reversal of 2019-2021 increases






2023 number of deaths 23% below level of 2015, almost one third of the way to 2025 milestone





COVID-related disruptions resulted in almost 700,000 excess deaths from TB



Shaded area between solid blue and red lines: excess deaths in 2020, 2021, 2022, 2023



In 2023, TB probably returned to being the leading cause of death from an infectious disease

Estimated number of TB deaths among HIV-negative people*

1.09 million

(95% UI: 0.98–1.20)

Officially reported number of deaths from COVID-19

320,000

Estimated number of deaths from HIV/AIDS


0.63 million

(95% UI: 0.61-0.66)



Better progress in reducing TB incidence rate in 2 regions

African Region &
European
Region
estimated to
have passed
first Strategy
milestone
(20% reduction
from 2015)




Dashed lines show 2025 milestone of the End TB Strategy: 50% reduction, 2015–2025

Shaded areas show 95% uncertainty intervals




79 countries estimated to have achieved reduction of ≥20% since 2015



Better progress in reducing TB deaths in 2 regions

African
Region &
European
Region
estimated
to have
passed first
Strategy
milestone
(35%
reduction
from 2015)

Total TB deaths per year (thousands)




Dashed lines show 2025 milestone of the End TB Strategy: 75% reduction, 2015–2025

Shaded areas show 95% uncertainty intervals



countries estimated to have achieved reduction of ≥35% since 2015




Estimation of TB disease burden during COVID-19 pandemic and its aftermath is difficult

- Country and region-specific dynamic models relied upon for low and middle-income countries with large absolute or relative reductions in TB case notifications (beyond historical trends) in 2020 and/or 2021
- New direct measurements of disease burden needed
 - National VR systems
 - National TB prevalence surveys*
 - National inventory studies to measure underreporting**

^{*}Surveys recently completed in Cambodia (3rd survey) and Timor-Leste; 12 countries considering repeat surveys: Bangladesh, Ethiopia, Ghana, Indonesia, Malawi, Nigeria, Pakistan, Thailand, Uganda, Tanzania, Zambia, Zimbabwe.
**Second study completed in 2023 in Indonesia (see the report "featured topics"; planned in the Philippines and Viet Nam




Estimated number of people developing MDR/RR-TB relatively stable from 2020–2023






Declines in proportion of people with TB who have MDR/RR-TB, 2015–2023

People with no previous history of TB treatment



People previously treated for TB






TB diagnosis & treatment




Further global recovery in number of people newly diagnosed with TB, to new historic high

Numbers in 2022 & 2023 probably include sizeable backlog of people whose diagnosis was delayed by COVID disruptions





Further narrowing of global gap between estimated number of people falling ill with TB and reported number newly diagnosed




Case notifications in 2022 & 2023 probably include sizeable backlog of people whose diagnosis was delayed by COVID disruptions



TB treatment coverage* appears to have recovered to above pre-pandemic levels


*Approximated as the number of people newly diagnosed in a given year divided by estimated TB incidence in the same year



Estimates for
2022 and 2023
probably
distorted by
sizeable backlog
of people newly
diagnosed in
2022 and 2023,
whose diagnosis
was delayed
during COVID
disruptions




Number of people diagnosed & treated for MDR/RR-TB virtually stable and considerably below estimated number developing MDR/RR-TB each year






Treatment success rates Sustained or improving






10 countries account for 67% of the global gap between TB incidence and reported cases





From global perspective, increased coverage of diagnosis and treatment of particular importance in these countries


Global stagnation in % of people diagnosed with TB that was bacteriologically confirmed





Global coverage of rapid testing

limited increase in coverage in 2023, but much higher number of people tested




TB prevention & screening

Most emphasis on TB preventive treatment (TPT)



Number of people provided with TPT* increasing, due to growing provision to household contacts




People living with HIV





Global coverage of TB preventive treatment improving for household contacts, stable for people living with HIV, both short of 90% target



90% target for 2027

People living with HIV newly enrolled on ART


Household contacts of people newly diagnosed with TB



Funding for TB diagnosis, treatment and prevention





Funding for TB prevention, diagnosis and treatment down since 2019 and only 26% of 2027 target





Funding has increased in high TB burden and global watchlist countries outside BRICS, and fallen in BRICS










UHC and TB determinants



Almost all high TB burden countries far from UHC*, based on status of SDG UHC indicators

with sanlar sanl

catastrophic health expenditures



*Universal health coverage


Everyone can access the health services they need without suffering financial hardship

Thailand closest

About half of people with TB and their households face catastrophic costs

pooled average = 49%; far above End TB Strategy target of zero

35
countries
including
18 high TB
burden
countries
and 1
global TB
watchlist
country





Even higher for people with drug-resistant TB: pooled average 82%



TB incidence rate is strongly associated with average income levels and undernutrition


Each dot represents a country or area





A large number of new TB cases are attributable to five risk factors:

undernutrition, alcohol use, smoking, HIV infection, diabetes



Number of attributable cases (millions)



TB research



Requirements to reach 2030 and 2035 targets

Technological breakthrough by 2025, to enable acceleration of decline in TB incidence to far beyond levels achieved historically

e.g. a new TB vaccine



Status of pipelines for diagnostics, drugs and vaccines*

50+ diagn

diagnostic tests for TB disease and infection in development

clinical trials and other research studies for treatment of <u>TB infection</u>

29


drugs for treatment of TB disease in clinical trials

15

<u>vaccine</u> candidates in clinical trials



Funding for TB research growing very slowly and insufficient, only 20% of global target





Conclusions




Global tuberculosis report

Overarching conclusion

Ending the global TB epidemic requires translating the commitments made at the 2023 UN high-level meeting on TB into action



Summary of progress towards global TB targets




See Introduction facing page in the report

For more information



Report landing page



Report app

